Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Florbetaben PET for Cerebral Amyloid Beta Detection in AD
NCT00750282Phase 2Completed
- Sponsor
- Life Molecular Imaging
- Start
- Aug 2008
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of florbetaben in Alzheimer's disease (AD), sponsored by Life Molecular Imaging. Primary endpoints: Specificity of Florbetaben PET Scans and Sensitivity of Florbetaben PET Scans. Started Aug 2008; status: completed.
02
Drugs
florbetaben
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00750282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00750282.